GlassScriptPhysician profile
Sang Huh
NPI 1194799742
$18,259.68
in general payments reported to CMS, 2019-2025
79 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,108 · 2020: $1,659 · 2021: $2,063 · 2022: $2,893 · 2023: $3,251 · 2024: $3,585 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,619 · Education: $1,236 · Long Term Medical Supply Or Device Loan: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,619.42 |
| Education | $1,235.66 |
| Long Term Medical Supply Or Device Loan | $681.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,193.47 | 2019-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $1,339.85 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Janssen Biotech, INC. | $1,178.94 | 2019-2024 | Tecvayli, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $986.61 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $854.12 | 2019-2023 | Padcev, Adcetris |
| Astellas Pharma US INC | $809.87 | 2020-2024 | Xtandi, Padcev |
| Pfizer INC. | $784.06 | 2019-2025 | |
| Eisai INC. | $545.18 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $531.42 | 2019-2025 | Opdivo, Augtyro |
| Genzyme Corporation | $531.24 | 2019-2025 | |
| Gilead Sciences, INC. | $516.56 | 2021-2025 | Trodelvy |
| Abbvie INC. | $485.19 | 2019-2025 | |
| Genentech USA, INC. | $472.41 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Celgene Corporation | $449.93 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $428.19 | 2019-2025 | Enhertu, Injectafer |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.05 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Incyte Corporation | $315.73 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $301.95 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Exelixis INC. | $284.43 | 2019-2024 | Cabometyx |
| Lilly USA, LLC | $267.10 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Rigel Pharmaceuticals, INC. | $251.66 | 2019-2025 | Tavalisse, Rezlidhia, Tavalisse |
| Novocure Gmbh | $250.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $196.89 | 2019-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $179.74 | 2019-2025 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.70 | 2019-2024 | |
| Array Biopharma INC | $169.61 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Sobi, INC | $165.15 | 2022-2024 | |
| Glaxosmithkline, LLC. | $161.37 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Morphosys, US INC. | $152.50 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $150.14 | 2022-2025 | Besremi |
| Beigene USA, INC. | $143.27 | 2020-2023 | Brukinsa |
| Emd Serono, INC. | $143.13 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $141.74 | 2021-2025 | Monoferric, Cosela |
| Coherus Oncology, INC. | $131.56 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $129.77 | 2021-2025 | |
| Tersera Therapeutics LLC | $120.04 | 2020-2025 | Xermelo, Zoladex |
| Genmab U.S., INC. | $111.19 | 2022-2025 | Epkinly, Tivdak |
| Blueprint Medicines Corporation | $103.12 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $100.67 | 2019-2024 | Xarelto |
| Clovis Oncology, INC. | $99.27 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $90.74 | 2020-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $90.03 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $89.00 | 2023 | |
| Foundation Medicine, INC. | $86.68 | 2019-2022 | |
| Puma Biotechnology, INC. | $83.22 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $75.75 | 2022-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $72.35 | 2024-2025 | |
| Acceleron Pharma, INC. | $64.88 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $63.15 | 2021-2024 | Clonoseq |
| Agios Pharmaceuticals, INC. | $59.17 | 2019-2020 | |
| Eusa Pharma (US) LLC | $58.71 | 2019-2022 | |
| Genentech, INC. | $49.95 | 2021 | |
| Acrotech Biopharma INC. | $49.50 | 2023-2024 | Beleodaq |
| Apellis Pharmaceuticals, INC. | $47.89 | 2023 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $47.15 | 2022-2025 | Onivyde, Somatuline Depot |
| Geron Corporation | $44.87 | 2025 | Rytelo |
| Taiho Oncology, INC. | $41.51 | 2023-2025 | |
| Macrogenics, INC. | $37.72 | 2022 | |
| Sun Pharmaceutical Industries INC. | $32.22 | 2022-2024 | |
| Kite Pharma, INC. | $29.00 | 2021-2023 | |
| Cti Biopharma Corp. | $26.28 | 2022 | |
| Spectrum Pharmaceuticals INC. | $25.43 | 2023 | Rolvedon |
| Caris Mpi, INC. | $24.58 | 2025 | Mi Cancer Seek |
| Syndax Pharmaceuticals, INC. | $22.70 | 2025 | Revuforj |
| Immunocore Limited | $22.30 | 2024 | Kimmtrak |
| Organon LLC | $21.94 | 2021 | |
| Epizyme, INC. | $20.14 | 2020 | |
| Octapharma USA, INC. | $19.87 | 2024 | Octagam Immune Globulin (Human) |
| Legend Biotech USA INC. | $19.77 | 2025 | Carvykti |
| Tolmar, INC. | $16.25 | 2023 | |
| Beone Medicines USA, INC. | $16.20 | 2025 | Brukinsa |
| Tolmar Pharmaceuticals, INC. | $15.89 | 2022 | |
| Recordati_rare_diseases_inc. | $15.50 | 2025 | Enjaymo |
| Kyowa Kirin, INC. | $14.18 | 2024 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $14.12 | 2023 | Akynzeo |
| Adc Therapeutics America, INC. | $12.89 | 2022 | |
| Global Blood Therapeutics, INC. | $12.35 | 2020 | |
| G1 Therapeutics, INC. | $11.66 | 2022 | |
| Dova Pharmaceuticals | $11.32 | 2019 |
Drugs and devices associated with these payments
Kisqali $979Keytruda $449Enhertu $389Trodelvy $346Xtandi $258Reblozyl $254Tecvayli $229Lynparza $188Welireg $186Darzalex $180Lenvima $172Doptelet $153Adcetris $151Padcev $149Imbruvica $132Besremi $132Mektovi $131Epkinly $126Lutathera $126Scemblix $120Elrexfio $120Jakafi $117Braftovi $117Opdivo $117Inlyta $114Tecentriq $109Jevtana $107Venclexta $104Erleada $104Lorbrena $103Talzenna $97.80Cabometyx $90.43Ibrance $85.81Jaypirca $80.17Ultomiris $79.89Brukinsa $79.04Bosulif $77.79Xermelo $76.34Fabhalta $76.15Tavalisse $72.23Xalkori $72.08Zepzelca $71.13Comirnaty $70.86Soliris $69.99Monoferric $67.80Orgovyx $67.24Piqray $66.74Pluvicto $63.94Rybrevant $62.12Tasigna $60.07Libtayo $59.93Paxlovid $57.88Rezlidhia $56.70Tukysa $56.55Udenyca $56.45Sarclisa $56.26Alecensa $52.45Rozlytrek $52.45Monjuvi $51.64Carvykti $51.38Tibsovo $51.30Clonoseq $49.87Beleodaq $49.50Pomalyst $49.06Empaveli $47.89Eliquis $47.51Calquence $45.44Rytelo $44.87Promacta $44.85Polivy $44.38Phesgo $44.38Lonsurf $41.51Mekinist $37.31Nubeqa $36.55Xofigo $36.55Somatuline Depot $34.49Onivyde $34.49Xpovio $34.11Gavreto $32.56Vectibix $31.80Nplate $31.80Xgeva $31.80Besponsa $31.47Fruzaqla $31.46Lumakras $31.23Oxbryta $30.90Enjaymo $30.86Columvi $30.44Lunsumio $30.44Zejula $28.90Jemperli $28.90Ojjaara $28.81Akynzeo $28.24Bavencio $26.93Rolvedon $25.43Xarelto $25.17Injectafer $25.01Mi Cancer Seek $24.58Iclusig $23.75Revuforj $22.70
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sang Huh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.